Effectiveness and safety of tocilizumab treatment for chronic active antibody-mediated rejection in kidney transplant recipients.
- DOI
- 10.23876/j.krcp.25.181
- Published
- 2025 Dec 12
- Container
- Kidney research and clinical practice
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.23876/j.krcp.25.181,
title = {Effectiveness and safety of tocilizumab treatment for chronic active antibody-mediated rejection in kidney transplant recipients.},
author = {Lee HE and Park H and Lee H and Choi YJ and Oh EJ and Chung BH},
year = {2025},
journal = {Kidney research and clinical practice},
doi = {10.23876/j.krcp.25.181},
url = {https://doi.org/10.23876/j.krcp.25.181}
}RIS
TY - JOUR TI - Effectiveness and safety of tocilizumab treatment for chronic active antibody-mediated rejection in kidney transplant recipients. AU - Lee HE AU - Park H AU - Lee H AU - Choi YJ AU - Oh EJ AU - Chung BH PY - 2025 JO - Kidney research and clinical practice DO - 10.23876/j.krcp.25.181 UR - https://doi.org/10.23876/j.krcp.25.181 ER -
APA
HE, L., H, P., H, L., YJ, C., EJ, O., & BH, C. (2025). Effectiveness and safety of tocilizumab treatment for chronic active antibody-mediated rejection in kidney transplant recipients.. Kidney research and clinical practice. https://doi.org/10.23876/j.krcp.25.181
Source records
- pubmed · retrieved 2026-09-25T09:08:03.630Z